{
    "nct_id": "NCT04089449",
    "official_title": "A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of PRT811 in Subjects With Advanced Solid Tumors, CNS Lymphoma, and Recurrent High-Grade Gliomas",
    "inclusion_criteria": "* Malignancies that are refractory to or intolerant of established therapies known to provide clinical benefit for the malignancy in question, or in the opinion of the Investigator, not be a candidate for such therapies\n* Subjects must have recovered from the effects of any prior investigational system therapies\n* For subjects with recurrent high-grade glioma or GBM, must have biopsy proven evidence (WHO Grade III or IV) and received external bean fractionated radiotherapy and at least 2 cycles of adjuvant temozolomide chemotherapy. Mutant Glioma must comply with biomarker defined enrollment criterias.\n* For biomarker-selected solid tumors: must meet enrollment criteria\n* Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1\n* Adequate organ function (bone marrow, hepatic, renal, cardiovascular)\n* Female subjects of childbearing potential must have a negative pregnancy test within 7 days of the start of treatment and must agree to use an effective method of contraception during the trial\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Untreated concurrent malignancies or malignancies that have been in complete remission for less than one year\n* Treatment with strong inhibitors of CYP3A4 for which there are no therapeutic substitutions\n* Inflammatory disorders of the gastrointestinal tract, or subjects with GI malabsorption\n* HIV positive; known active hepatitis B or C\n* Known hypersensitivity to any of the components of PRT811",
    "miscellaneous_criteria": ""
}